ArticleJournal of psychiatric research2023
The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder.
Article in Journal of psychiatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pooled it
- The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults.Journal of child and adolescent psychopharmacology · 2024Pooled it
- Genetics, epigenetics, and neurobiology of childhood-onset depression: an umbrella review.Molecular psychiatry · 2024Pooled it
- The effects of a salsa dance intervention in young people with mild to moderately severe depressive symptoms.Psychological medicine · 2026Trial
- Associations of perceived helpfulness of depression treatment modality with symptom severity and substance use disorder.Discover mental health · 2026Article
- Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- From fragmentation to integration: can social prescribing bridge the gap between multimorbidity and mental health in an ageing population?BMJ public health · 2026Review
- Reinitiation of antidepressant pharmacotherapy among patients discharged from the hospital: A population-based cohort study.PLOS mental health · 2026Article
- The relevance of phenotypic definition in treatment resistant forms of major depressive disorder: a narrative review.Frontiers in pharmacology · 2026Review
- Personalizing Antidepressant Therapy: Integrating Pharmacogenomics, Therapeutic Drug Monitoring, and Digital Tools for Improved Depression Outcomes.Journal of personalized medicine · 2025Review
- Article
- Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents.Pharmaceutics · 2025Article
- Understanding anhedonia in major depressive disorder in Japan: epidemiology and unmet needs from patients' and physicians' perspectives.BMC psychiatry · 2025Observational
- Association Between Prehip Fracture Antidepressant Use and Posthip Fracture Length of Hospital Stay in Medicare Beneficiaries and Assessing Sex Differences.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2025Article
- Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics.Focus (American Psychiatric Publishing) · 2025Review
- Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank.Psychological medicine · 2025Article
- Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression.Frontiers in psychiatry · 2025Article
- At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.Journal of affective disorders · 2024Article
- Personalized venlafaxine dose prediction using artificial intelligence technology: a retrospective analysis based on real-world data.International journal of clinical pharmacy · 2024Article
- Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.Journal of psychopharmacology (Oxford, England) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
introductionUnderstanding how age affects antidepressant response in patients with major depressive disorder has been complicated by small and heterogeneous studies. Yet, understanding how age-across the lifespan-contributes to variation in response could inform treatment selection across the lifespan. This study sought to identify how age impacts antidepressant response using participant-level data from large, NIH-sponsored trials in individuals with MDD aged 12-74 years. MATERIALS AND
methodsParticipant-level data were abstracted from three NIH-sponsored trials of pharmacotherapy (Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study, Treatment of Adolescent Depression Study (TADS), and the Combining Medications to Enhance Depression Outcomes Study (COMED)) in patients with MDD. Bayesian Hierarchical Models (BHMs) of individual treatment trajectories were developed using Hamiltonian Monte Carlo No U-Turn Sampling. The individual trajectory of improvement in depressive symptoms (Clinical Global Impression-Severity [CGI-S] and CGI-S equivalent from COMED) was modeled across studies and across individuals with logarithmic trend "random effects" coefficients BHMs. Age and sex (and their interaction) were examined categorically across patients.
resultsStudy participants (N = 907) were 29.7 ± 17 years of age, 66.3% women, and had a mean baseline CGI-S score of 4.6 ± 0.9. Patients ≤21 years and those >55 years had slower and less response to pharmacotherapy compared to those aged 21-35. Additionally, women improved more than men, and this effect did not differ across ages. DISCUSSION: The patient's age should be considered in predicting antidepressant response, particularly in older and younger individuals who may benefit from other interventions to enhance treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.